Towards the structure-based design of oligonucleotide therapeutics

Advances in Enzyme Regulation

Volumn 38, Issue 1, 1998, Pages 181-203

  Egli, Martin ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBONUCLEASE; DNA; NUCLEASE; OLIGONUCLEOTIDE; RIBONUCLEASE;

CANCER; CHEMICAL STRUCTURE; CHEMISTRY; CONFERENCE PAPER; CONFORMATION; CRYSTALLIZATION; DNA DEGRADATION; DRUG DESIGN; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; METABOLISM; PROTEIN SYNTHESIS; RNA DEGRADATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DEOXYRIBONUCLEASES; DNA; DRUG DESIGN; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASES;

EID: 0031857102     PISSN: 00652571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0065-2571(97)00004-6     Document Type: Conference Paper

References (88)

1. E. UHLMANN and A. PEYMAN, Antisense oligonucleotides: A new therapeutic principle, Chem. Rev. 90, 543-584 (1990).
2. R. S. VARMA, Synthesis of oligonucleotide analogues with modified backbones, Synlett , 621-637 (1993).
3. S. T. CROOKE and B. LEBLEU, Antisense Research and Applications, CRC Press, Boca Raton, FL (1993).
4. J. F. MILLIGAN, M. D. MATTEUCCI and J. C. MARTIN, Current concepts in antisense drug design, J. Med. Chem. 36, 1923-1937 (1993).
5. Y. S. SANGHVI and P. D. COOK, Carbohydrate Modifications in Antisense Research, ACS Symp. Ser. 580, Am. Chem. Soc., Washington D.C. (1994).
6. A. DE MESMAEKER, R. HANER, P. MARTIN and H. E. MOSER, Antisense oligonucleotides, Acc. Chem. Res. 28, 366-374 (1995).
7. S. AGRAWAL, Methods in Molecular Medcine: Antisense Therapeutics, Humana Press, Totowa, NJ (1996).
8. S. T. CROOKE, Antisense oligonucleotides, pp. 299-366 in Cancer Therapeutics: Experimental and Clinical Agents, (B. A. TEICHER, ed.). Humana Press, Totowa, NJ (1996).
9. V. N. SOYFER and V. N. POTAMAN, Triple-Helical Nucleic Acids, Springer-Verlag, New York, NY (1996).
10. P. C. ZAMECNIK and M. L. STEPHENSON, Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide, Proc. Natl. Acad. Sci. U.S.A. 75, 280-284 (1978).
11. M. L. STEPHENSON and P. C. ZAMECNIK, Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide, Proc. Natl. Acad. Sci. U.S.A. 75, 285-288 (1978).
12. M. MANOHARAN, Designer antisense oligonucleotides: conjugation chemistry and functionality placement, pp. 303-349 in Antisense Research and Applications, (S. T. CROOKE and B. LEBLEU, eds.). CRC Press, Boca Raton, FL (1993).
13. A. DE MESMAEKER, K.-H. ALTMANN, A. WALDNER and S. WENDEBORN, Backbone modifications in oligonucleotides and peptide nucleic acid systems, Curr. Opin. Struct. Biol. 5, 343-355 (1995).
14. S. M. FREIER and K-H. ALTMANN, The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically modified DNA:RNA duplexes, Nucleic Acids Res. 25, 4429-4443 (1997).
15. R. W. WAGNER, M. D. MATTEUCCI, G. J. LEWIS, A. J. GUTIERREZ, C. MOULDS and B. C. FRÖHLER, Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science 260, 1510-1513 (1993).
16. B. P. MONIA, H. SASMOR, J. F. JOHNSTON, S. M. FREIER, E. A. LESNIK, M. MÜLLER, T. GEIGER, K-H. ALTMANN, H. MOSER and D. FABBRO, Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo, Proc. Natl. Acad. Sci. U.S.A. 93, 15481-15484 (1996).
17. B. F. BAKER, S. S. LOT, T. P. CONDON, S. CHENG-FLOURNEY, E. A. LESNIK, H. M. SASMOR and C. F. BENNETT, 2′-O-(2-Methyoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level by formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells, J. Biol. Chem. 272, 11994-12000 (1997).
18. P. MARTIN, A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides, Helv. Chim. Acta 78, 486-504 (1995).
19. K-H. ALTMANN, N. M. DEAN, D. FABBRO, S. M. FREIER, T. GEIGER, R. HANER, D. HÜSKEN, P. MARTIN, B. P. MONIA, M. MÜLLER, F. NATT, P. NICKLIN, J. PHILLIPS, U. PIELES, H. SASMOR and H. E. MOSER, Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals, Chimia 50, 168-176 (1996).
20. K-H. ALTMANN, D. FABBRO, N. M. DEAN, T. GEIGER, P. MONIA, M. MÜLLER and P. NICKLIN, Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors, Biochem. Soc. Trans. 24, 630-637 (1996).
21. R. H. GRIFFEY, B. P. MONIA, L. L. CUMMINS, S. FREIER, M. J. GREIG, C. J. GUINOSSO, E. A. LESNIK, S. M. MANALILI, V. MOHAN, S. OWENS, B. R. ROSS, H. SASMOR, E. WANCEWICZ, K. WEILER, P. D. WHEELER and P. D. COOK, 2′-O-Aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides, J. Med. Chem. 39, 5100-5109 (1996).
22. S. M. GRYAZNOV and J. K. CHEN, Oligodeoxyribonucleotide N3′ → P5′ phosphoramidates: Synthesis and hybridization properties, J. Am. Chem. Soc. 116, 3143-3144 (1994).
23. S. M. GRYAZNOV, D. H. LLOYD, J-K. CHEN, R. G. SCHULTZ, L. A. DEDIONISIO, L. RATMEYER and W. D. WILSON, Oligonucleotide N3′ → P5′ phosphoramidates, Proc. Natl. Acad. Sci. U.S.A. 92, 5798-5802 (1995).
24. F. ECKSTEIN, Nucleoside phosphorothioates, Ann. Rev. Biochem. 54, 367-402 (1985).
25. W. S. MARSHALL and M. H. CARUTHERS, Phosphorodithioate DNA as a potential therapeutic drug, Science 259, 1564-1570 (1993).
26. D. E. SZYMKOWSKI, Developing antisense oligonucleotides from laboratory to clinical trials, Drug Discov. Today 1, 415-428 (1996).
27. S. AKHTAR and S. AGRAWAL, In vivo studies with antisense oligonucleotides, Trends Pharmacol. Sci. 18, 12-19 (1997).
28. Antisense '97: A roundtable on the state of the industry, Feature article in Nature Biotechn. 15, 519-524 (1997).
29. P. D. COOK., Antisense Medicinal Chemistry. In Protocols in Experimental Pharmacology, ed. S. T. CROOKE, Springer, New York, NY. 1997 (in press).
30. J. TANG, A. ROSKEY, Y. LI and S. AGRAWAL, Enzymatic synthesis of stereoregular (all Rp) oligonucleotide phosphorothioate and its properties, Nucleosides & Nucleotides 14, 985-990 (1995).
31. W. J. STEC, A. GRAJKOWSKI, A. KOBYLANSKA, B. KARWOWSKI, M. KOZIOLKIEWICZ, K. MISIURA, A. OKRUSZEK, A. WILK, P. GUGA and M. BOCZKOWSKA, Diastereomers of nucleoside 3′-O-(2-Thio-1,3,2-oxathia(selenaphospholanes): Building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s, J. Am. Chem. Soc. 117, 12019-12029 (1995).
32. H. KANEHARA, T. WADA, M. MIZUGUCHI and K. MAKINO, Influence of a thiophosphate linkage on the duplex stability - does Sp configuration always lead to higher stability than Rp?, Nucleosides & Nucleotides 15, 1169-1178 (1996).
33. M. KOZIOLKIEWICZ, M. WOJCIK, A. KOBYLANSKA, B. KARWOWSKI, B. REBOWSKA, P. GUGA and W. J. STEC. Stability of stereoregular oligo(nucleoside phosphorothioate)s pp. 43-48 in Human Plasma: Diastereoselectivity of plasma 3′-exonuclease. Antisense & Nucleic Acid Drug Development, vol. 7 (1997).
34. J. C. WANG and G. JUST, A stereoselective synthesis of dinucleotide phosphorothioates, using chiral indol-oxazaphosphorine intermediates, Tetrahedron Lett. 38, 3797-3800 (1997).
35. M. J. GREIG, H. GAUS, L. L. CUMMINS, H. SASMOR and R. H. GRIFFEY, Measurement of macromolecular binding using electrospray mass spectrometry. Determination of dissociation constants for oligonucleotide-serum albumin complexes, J. Am. Chem. Soc. 117, 10765-10766 (1995).
36. S. T. CROOKE, M. J. GRAHAM, J. E. ZUCKERMAN, D. BROOKS, B. S. CONKLIN, L. L. CUMMINS, M. J. GREIG, C. J. GUINOSSO, D. KORNBRUST, M. MANOHARAN, H. M. SASMOR, T. SCHLEICH, K. L. TIVEL and R. H. GRIFFEY, Pharmacokinetic properties of several novel oligonucleotide analogs in mice, J. Pharm. Expr. Therap. 277, 923-937 (1996).
37. S. AGRAWAL, X. ZHANG, Z. LU, H. ZHAO, J. M. TAMBURIN, J. YAN, H. CAI, R. B. DIASIO, I. HABUS, Z. JIANG, R. P. IYER, D. YU and R. ZHANG, Absorption, tissue distribution and in vivo stability in rats of a hybrid anti-sense oligonucleotide following oral administration, Biochem. Pharm. 50, 571-576 (1995).
38. P. HERDEWIJN, Targeting RNA with conformationally restricted oligonucleotides, Liebigs Ann. 1337-1348 (1996).
39. M. EGLI, Structural aspects of nucleic acid analogs and antisense oligonucleotides, Angew. Chem. Int. Ed. Engl. 35, 1894-1909 (1996).
40. L. L. CUMMINS, S. R. OWENS, M. L. RISEN, E. A. LESNIK, S. M. FREIER, D. McGEE, C. J. GUINOSSO and P. D. COOK, Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity, Nucleic Acids Res. 23, 2019-2024 (1995).
41. E. A. LESNIK, C. J. GUINOSSO, A. M. KAWASAKI, H. SASMOR, M. ZOUNES, L. L. CUMMINS, D. J. ECKER, P. D. COOK and S. M. FREIER, Oligodeoxynucleotides containing 2′-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes, Biochemistry 32, 7832-7838 (1993).
42. A. M. KAWASAKI, M. D. CASPER, S. M. FREIER, E. A. LESNIK, M. C. ZOUNES, L. L. CUMMINS, C. GONZALEZ and P. D. COOK, Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets, J Med. Chem. 36, 831-841 (1993).
43. R. G. SCHULTZ and S. M. GRYAZNOV, Oligo-2′-fluoro-2′-deoxynucleotide N3′ → P5′ phosphoramidates: synthesis and properties, Nucleic Acids Res. 24, 2966-2973 (1996).
44. C. MOULDS, J. G. LEWIS, B. C. FROEHLER, D. GRANT, T. HUANG, J. F. MILLIGAN, M. D. MATTEUCCI and R. W. WAGNER, Site and mechanism of anti-sense inhibition by C-5 propyne oligonucleotides, Biochemistry 34, 5044-5053 (1995).
45. W. F. LIMA and S. T. CROOKE, Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids, Biochemistry 36, 5004-5019 (1997).
46. W. F. LIMA, V. MOHAN and S. T. CROOKE, The influence of antisense oligonucleotide-induced RNA structure on E. coli RNase H1 activity, J. Biol. Chem. 272, 18191-18199 (1997).
47. O. HEIDENREICH, S. GRYAZNOV and M. NERENBERG, RNase H-independent antisense activity of oligonucleotide N3′ → P5′ phosphoramidates, Nucleic Acids Res. 25, 776-780 (1997).
48. P. D. COOK, Medicinal chemistry of antisense oligonucleotides - future opportunities, Anti-Cancer Drug Design 6, 585-607 (1991).
49. P. D. COOK, Medicinal chemistry strategies for antisense research, pp. 149-187 in Antisense Research and Applications, (S. T. CROOKE and B. LEBLEU, eds.). CRC Press, Boca Raton, FL (1993).
50. B. P. MONIA, E. A. LESNIK, C. GONZALEZ, W. F. LIMA, D. MCGEE, C. J. GUINOSSO, A. M. KAWASAKI, P. D. COOK and S. M. FREIER, Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression, J. Biol. Chem. 268, 14514-14522 (1993).
51. A. ZIEGLER, G. LUEDKE, D. FABBRO, K.-H. ALTMANN, R. A. STAHEL and U. ZANGEMEISTER-WITTKE, Evaluation of antisense sequences directed against the bcl-2 mRNA reveals a novel oligonucleotide targeting the coding region as potent inducer of apoptosis in small cell lung cancer, J. Natl. Cancer Inst. 89, 1027-1036 (1997).
52. C. F. BENNETT, N. DEAN, D. J. ECKER and B. P. MONIA, Pharmacology of antisense therapeutic agents, pp. 13-46 in Methods in Molecular Medicine: Antisense Therapeutics, (S. AGRAWAL, ed.). Humana Press, Totowa, NJ (1996).
53. S. PORMANN, K.-H. ALTMANN, N. REYNES and M. EGLI, Crystal structures of oligodeoxyribonucleotides containing 6′-α-methyl and 6′-α-hydroxy carbocyclic thymidines, J. Am. Chem. Soc. 119, 2396-2403 (1997).
54. M. EGLI, P. LUBINI, M. BOLLI, M. DOBLER and C. LEUMANN, Crystal structure of a parallel-stranded duplex of a deoxycytidylyl-(3′-5′)-deoxycytidine analogue containing intranucleosidyl C(3′)-C(5′) ethylene bridges, J. Am. Chem. Soc. 115, 5855-5856 (1993).
55. P. LUBINI and M. EGLI, A parallel-stranded double helix at atomic resolution, pp. 155-175 in Structural Biology: The State of the Art Proceedings of the Eighth Conversation, State University of New York, Albany, NY 1993. Vol. 2. (R. H. SARMA and M. H. SARMA, eds). Adenine Press, Schenectady, NY (1994).
56. A. L. ROUGHTON, S. PORTMANN, S. A. BENNER and M. EGLI, Crystal structure of a dimethylene sulfone linked ribodinucleotide analog, J. Am. Chem. Soc. 117, 7249-7250 (1995).
57. V. TERESHKO, S. GRYAZNOV and M. EGLI, Consequences of replacing the DNA 3′-oxygen by an amino group: High-resolution crystal structure of a fully modified N3′ → P5′ phosphoramidate DNA dodecamer duplex, J. Am. Chem. Soc. 120, 269-283 (1998).
58. L. BEIGELMAN, A. KARPEISKY and U. USMAN, Synthesis of 5′-C-methyl-D-allo-& L-talo-ribonucleoside 3′-O-phosphoramidates & their incorporation into hammerhead ribozymes, Nucleosides & Nucleotides 14, 901-905 (1995).
59. P. LUBINI, W. ZÜRCHER and M. EGLI, Stabilizing effects of the RNA 2′-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2′-O-methylated adenosines, Chem. & Biol. 1, 39-45 (1994).
60. J. MATULIC-ADAMIC, L. BEIGELMAN, S. PORTMANN, M. EGLI and N. USMAN, Synthesis and structure of 1-deoxy-1-phenyl-β-D-ribofuranose and its incorporation into oligonucleotides, J. Org. Chem. 61, 3909-3911 (1996).
61. M. EGLI, S. PORTMANN and N. USMAN, RNA hydration: A detailed look, Biochemistry 35, 8489-8494 (1996).
62. M. EGLI, N. USMAN and A. RICH, Conformational influence of the ribose 2′-hydroxyl group: Crystal structures of DNA-RNA chimeric duplexes, Biochemistry 32, 3221-3237 (1993).
63. C. BAN, B. RAMAKRISHNAN and M. SUNDARALINGAM, A single 2′-hydroxyl group converts B-DNA to A-DNA. Crystal structure of the DNA-RNA chimeric decamer d(CCGGC)r(G)d(CCGG) with a novel intermolecular G•C base-paired quadruplet, J. Mol. Biol. 236, 275-285 (1994).
64. N. C. HORTON and B. C. FINZEL, The structure of an RNA/DNA hybrid: A substrate of the ribonuclease activity of HIV-1 reverse transcriptase, J. Mol. Biol. 264, 521-533 (1996).
65. M. EGLI, S. PORTMANN, D. TRACZ, C. WORKMAN and N. USMAN, Crystallization and preliminary X-ray diffraction analysis of double-helical RNA octamers, Acta Cryst. D 51, 1065-1070 (1995).
66. S. PORTMANN, N. USMAN and M. EGLI, The crystal structure of r(CCCCGGGG) in two distinct lattices, Biochemistry 34, 7569-7575 (1995).
67. J. JANCARIK and S-H. KIM, Sparse matrix sampling: a screening method for crystallization of proteins, J. Appl. Crystallogr. 24, 409-411 (1991).
68. W. G. SCOTT, J. T. FINCH, R. GRENFELL, J. FOGG, T. SMITH, M. J. GAIT and A. KLUG, Rapid crystallization of chemically synthesized "hammerhead" RNAs using a "double-screening" procedure, J. Mol. Biol. 250, 327-332 (1995).
69. I. BERGER, C.-H. KANG, N. SINHA, M. WOLTERS and A. RICH, A highly efficient 24-condition matrix for the crystallization of nucleic acid fragments, Acta Crystallogr. D 52, 465-468 (1996).
70. C. W. CARTER, JR and C. W. CARTER, Protein crystallization using incomplete factorial experiments, J. Biol. Chem. 254, 12219-12223 (1979).
71. J. A. DOUDNA, C. GROSSHANS, A. GOODING and C. E. KUNDROT, Crystallization of ribozymes and small RNA motifs by a sparse matrix approach, Proc. Natl. Acad. Sci. U.S.A. 90, 7829-7833 (1993).
72. K. J. BAEYENS, J. JANCARIK and S. R. HOLBROOK, Use of low-molecular-weight polyethylene glycol in the crystallization of RNA oligomers, Acta Cryst. D 50, 764-767 (1994).
73. K-H. ALTMANN, M. O. BÉVIERRE, A. DE MESMAEKER and H. E. MOSER, The evaluation of 2′- and 6′-substituted carbocyclic nucleosides as building blocks for antisense oligonucleotides, Biorg. Med. Chem. Lett. 5, 431-436 (1995).
74. H. R. DREW and R. E. DICKERSON, Structure of a B-DNA dodecamer. III. Geometry of hydration, J. Mol. Biol. 151, 535-556 (1981).
75. M. L. KOPKA, A. V. FRATINI, H. R. DREW and R. E. DICKERSON, Ordered water structure around a B-DNA dodecamer. A quantitative study, J. Mol. Biol. 163, 129-146 (1983).
76. D. DING, S. M. GRYAZNOV, D. H. LLOYD, S. CHANDRASEKARAN, S. YAO, L. RATMEYER, Y. PAN and W. D. WILSON, An oligodeoxyribonucleotide N3′ → P5′ phosphoramidate duplex forms an A-type helix in solution, Nucleic Acids Res. 24, 354-360 (1996).
77. J. LEBRETON, A. WALDNER, C. LESUEUR and A. DE MESMAEKER, Antisense oligonucleotides with alternating phosphodiester-"amide-3" linkages, Synlett 137(140), (1994).
78. A. DE MESMAEKER, A. WALDNER, J. LEBRETON, P. N. HOFFMAN, V. FRITSCH, R. M. WOLF and S. M. FREIER, Amides as a new type of backbone modification in oligonucleotides, Angew. Chem. Int. Ed. Engl. 33, 226-229 (1994).
79. J.-J. VASSEUR, F. DEBART, Y. S. SANGHVI and P. D. COOK, Oligonucleosides-Synthesis of a novel methylhydroxylamine-linked nucleoside dimer and its incorporation into antisense sequences, J. Am. Chem. Soc. 114, 4006-4007 (1992).
80. F. MORVAN, Y. S. SANGHVI, M. PREBOST, J-J. VASSEUR and L. BELLON, Oligonucleotide mimics for antisense therapeutics: Solution phase and automated solid-support synthesis of MMI linked oligomers, J. Am. Chem. Soc. 118, 255-256 (1996).
81. P. E. NIELSEN, M. EGHOLM, R. H. BERG and O. BUCHARDT, Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide, Science 254, 1497-1500 (1991).
82. M. EGHOLM, O. BUCHARDT, L. CHRISTENSEN, C. BEHRENS, S. M. FREIER, D. A. DRIVER, R. H. BERG, S. K. KIM, B. NORDEN and P. E. NIELSEN, PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, Nature 365, 566-568 (1993).
83. P. E. NIELSEN, M. EGHOLM and O. BUCHARDT, Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone, Bioconjugate Chem. 5, 3-7 (1994).
84. J. SUMMERTON, D. STEIN, S. B. HUANG, P. MATTHEWS, S. WELLER and M. PARTRIDGE, Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems, Antisense Nucleic Acid Drug Dev. 7, 63-70 (1997).
85. L. BEIGELMAN, J. A. MCSWIGGEN, K. G. DRAPER, C. GONZALEZ, K. JENSEN, A. M. KARPEISKY, A. S. MODAK, J. MATULIC-ADAMIC, A. B. DIRENZO, P. HAEBERLI, D. SWEEDLER, D. TRACZ, S. GRIMM, F. E. WINCOTT, V. G. THACKRAY and N. USMAN, Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance, J. Biol. Chem. 270, 25702-25708 (1995).
86. J.-S. SUN and C. HÉLÈNE, Oligonucleotide-directed triple-helix formation, Curr. Opin. Struct. Biol. 3, 345-356 (1993).
87. M. F. KUBIK, T. FITZWATER, S. R. WATSON and D. M. TASSET, Isolation and characterization of 2-fluoro, 2-amino, and 2-fluoro/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding, J. Immunol. 159, 259-267 (1997).
88. C. T. RIGL, D. H. LLOYD, D. S. TSOU, S. GRYAZNOV and W. D. WILSON, Structural RNA mimetics: N3′ → P5′ phosphoramidate DNA analogs of HIV-1 RRE and TAR RNA form A-type helices that bind specifically to Rev and Tat-related pep tides, Biochemistry 36, 650-659 (1997).